Please select the outcome measures that correspond to the clinical trial below.
Title: Effect of Intermittent Versus Continuous Energy Restriction on Compensatory Mechanisms Activated During Weight Reduction
Brief Summary: Obesity has become a global epidemic with huge public health implications. Although clinical significant weight loss can be achieved by a combination of diet and behavioral modification, strong metabolic adaptations, with increased appetite and suppressed energy expenditure, are activated, which compromise weight loss maintenance and increase the risk of relapse. The aim of this project is to compare the effects of intermittent versus continuous energy restriction on the compensatory responses previously described using two low calory diets, with a similar macronutrient distribution. More specifically, this study will analyze, in the short-term, if an intermittent energy restricted diet is associated with less appetite and low reduction in energy expenditure when compared with a continuous energy restricted diet. This project can bring large practical benefits concerning the design of weight loss programs to minimize weight relapse.


Options:
A: Postprandial glucose response to meal test (3-hours)
B: Change From Baseline in Participant Glucose When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Human Growth Hormone (HGH) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Insulin When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Glycogen-Like Protein-1 (GLP-1) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Adiponectin When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Fibroblast Growth Factor-21 (FGF-21) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant White Blood Cell Count (WBC) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Hemoglobin When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Red Blood Cell Count (RBC) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Hematocrit When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Platelet Count When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Mean Corpuscular Volume (MCV) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Mean Corpuscular Hemoglobin (MCH) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Mean Corpuscular Hemoglobin Concentration (MCHC) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Red Cell Distribution Width (RDW) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Mean Platelet Volume (MPV) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Bicarbonate When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Sodium When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Chloride When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Blood Urea Nitrogen (BUN) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Calcium When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Potassium When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Creatinine When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Total Cholesterol (TC) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Low-Density Lipoprotein Cholesterol (LDL-C) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant High-Density Lipoprotein Cholesterol (HDL-C) When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Triglycerides When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant TC/HDL Ratio When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Weight When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Waist Circumference When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Systolic Blood Pressure (SBP), Supine When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant Diastolic Blood Pressure (DBP), Supine When Fasting and Fed (Baseline and 3 days); Change From Baseline in Participant High Sensitivity C-Reactive Protein (hsCRP) When Fasting and Fed (Baseline and 3 days)
C: Changes in gene expression in subcutaneous adipose tissue measured by whole genome sequencing (Assessments at baseline (week 0), and after the intervention phase (week 13))
D: Appetite related hormones (12 weeks after the intervention)

Answer: D